Gian Pal, MD
Neurology · New Brunswick, NJNPI 1629239371
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (56.5%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 11 manufacturers reported payments, led by Kyowa Kirin, Inc. at 37.8% of the total. Reporting peaked in 2022 at $6,240 and has fallen 94.5% since, to $343 in 2025.
Across 37 payments — averaging $407.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Kyowa Kirin, Inc.$6K
- AbbVie$3K
- Sanofi$2K
- Abbott$2K
- Acadia Pharmaceuticals Inc$646
- Eli Lilly$500
- plus $1K from 5 others
Across 35 payments — averaging $7197.73 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi$216K
- UCB SA$35K
- Medtronic$725
What the payments were for
- Consulting fees$4,75832%
- Speaking & faculty fees$8,51756%
- Travel & lodging$911%
- Food & beverage$1,71411%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Kyowa Kirin, Inc. | 5 | $5,706 |
| AbbVie | 2 | $3,240 |
| Sanofi | 1 | $2,345 |
| Abbott | 14 | $1,565 |
| Acadia Pharmaceuticals Inc | 3 | $646 |
| Eli Lilly | 1 | $500 |
| Medtronic | 6 | $433 |
| Vertex | 1 | $420 |
| Eisai Inc. | 1 | $122 |
| Boston Scientific | 1 | $71 |
| Amneal Pharmaceuticals LLC | 2 | $32 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NOURIANZ$5,623
- VYALEV$3,200
- Proclaim IPG$751
- NUPLAZID$638
- INFINITY$415
- PERCEPT PC BRAINSENSE$234
- Leqembi$122
How this compares
$15,079 in reported general payments places this provider in the 80th percentile of 521 neurology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 27 | $146,134 |
| RytaryCarbidopa/Levodopa | 59 | $130,581 |
| BotoxOnabotulinumtoxina | 20 | $20,141 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 245 | $14,105 |
| Rivastigmine | 41 | $11,146 |
| LinzessLinaclotide | 12 | $9,311 |
| AmantadineAmantadine Hcl | 106 | $3,585 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 114 | $2,312 |
| Selegiline Hcl | 20 | $2,189 |
| Rasagiline Mesylate | 14 | $2,073 |
| Gabapentin | 51 | $1,760 |
| Midodrine Hcl | 12 | $619 |
| Clonazepam | 108 | $587 |
| Propranolol Hcl ErPropranolol Hcl | 17 | $555 |
| Memantine Hcl | 13 | $466 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $646 | $146,13427 claims |
| Amneal Pharmaceuticals LLCRytary | $32 | $130,58159 claims |
| AbbVieBotox, Linzess | $3,240 | $29,45232 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 521 neurology providers in New Jersey.
Other neurology in New Brunswick
- Daniel SchneiderNew Brunswick$137K
- Suhayl Dhib-JalbutNew Brunswick$64K
- Steven BromleyAudubon$1.5M
- Mary Ann PiconeTeaneck$1.5M
- Fiona GuptaOradell$1.1M
- Matthew DavisMiddletown$567K
- Amos KatzEatontown$558K
- Monte PellmarFreehold$429K
- Marcie RabinSummit$387K
- Ashish KapoorBayonne$329K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.